CRC_INI 001

INI001 Prospective observational multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced non-small cell lung cancer.

This is an in vitro diagnostic (IVD) clinical validation study using Inivata’s liquid biopsy platform including enhanced TAm-Seq (eTAm-Seq) technology. The study will be a prospective observational multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced NSCLC.

Key Inclusion Criteria:
Patients intended to initiate first-line treatment according to standard guidelines, or having recently progressed on first-line EGFR or ALK directed therapy and being considered for further therapy. If enrolled in a treatment clinical trial, patients may enroll in this study if all eligibility criteria are met.

Patients who plan to have or have had a recent tumor tissue biopsy taken for molecular profiling as part of their standard of care.
N/A
NCT02906852
Cancer
Lung
Jason Lukas, M.D., Ph.D.
Inivata, Ltd.
Rachel Macomber
  • Providence Regional Cancer Partnership - Everett